← Evidence map

ArticleBreast cancer research and treatment2022

Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).

Charles E Geyer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2022

2023

this papercites it

Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology). | OpenQuestion